NEW YORK – Singapore-based molecular diagnostic company MiRxes announced Monday it has received CE marking and Provisional Authorization from the Singapore Health Sciences Authority for its multiplex SARS-CoV-2 and influenza A/B test.
NEW YORK – Singapore-based molecular diagnostic company MiRxes announced Monday it has received CE marking and Provisional Authorization from the Singapore Health Sciences Authority for its multiplex SARS-CoV-2 and influenza A/B test.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?
Login Now.
Don't have a GenomeWeb or 360Dx account?
Register for Free.